Literature DB >> 14609484

Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics.

Daniel Aletaha1, Josef S Smolen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14609484     DOI： 10.1007/s11926-003-0048-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  4 in total

Review 1.  Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies?

Authors:  C Bombardier; A Maetzel
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.

Authors:  D Aletaha; J S Smolen
Journal:  Rheumatology (Oxford)       Date:  2002-12       Impact factor: 7.580

Review 3.  Reevaluating the therapeutic approach to rheumatoid arthritis: the "sawtooth" strategy.

Authors:  J F Fries
Journal:  J Rheumatol Suppl       Date:  1990-05

4.  Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology.

Authors:  F Wolfe; M Lassere; D van der Heijde; G Stucki; M Suarez-Almazor; T Pincus; K Eberhardt; T K Kvien; D Symmons; A Silman; P van Riel; P Tugwell; M Boers
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666
  4 in total
  3 in total

Review 1.  Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.

Authors:  Juul M P A van den Reek; Wietske Kievit; Robert Gniadecki; Jelle J Goeman; Jeffrey Zweegers; Peter C M van de Kerkhof; Marieke M B Seyger; Elke M G J de Jong
Journal:  J Invest Dermatol       Date:  2015-07       Impact factor: 8.551

2.  Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure.

Authors:  Theresa Kapral; Tanja Stamm; Klaus P Machold; Karin Montag; Josef S Smolen; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2006-02-24       Impact factor: 5.156

3.  Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data.

Authors:  Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2009-06-03       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.